Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Jun 5, 2025; 16(2): 105801
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.105801
Table 1 Patient characteristics, n (%)
Number of patients
n = 80
Sex
Male29 (36.3)
Female51 (63.8)
Age66.156 ± 13.961
Bristol Stool Form Scale
Type 118 (22.5)
Type 232 (40)
Type 330 (37.5)
Type 40 (0)
Type 50 (0)
Type 60 (0)
Type 70 (0)
1-week frequency of bowel movements before elobixibat administration 2.013 ± 0.639
Number of drugs to relieve constipation before elobixibat administration
028 (35)
1 magnesium oxide tablet32 (40)
2 magnesium oxide tablets + sennoside20 (25)
Comorbidity
Hypertension38 (47.5)
Hyperlipidemia36 (45)
Diabetes mellitus35 (43.8)
Cerebrovascular disease16 (20)
Chronic respiratory disease13 (16.3)
Cardiac disease22 (27.5)
Chronic hepatic disease18 (22.5)
Chronic renal disease10 (12.5)
Malignant disease6 (7.5)
Post cholecystectomy18 (22.5)